• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Protein Sci . Epitope-directed anti-SARS-CoV-2 scFv engineered against the key spike protein region could block membrane fusion

tetano

Editor, Senior Moderator
Protein Sci


. 2023 Jan 23;e4575.
doi: 10.1002/pro.4575. Online ahead of print.
Epitope-directed anti-SARS-CoV-2 scFv engineered against the key spike protein region could block membrane fusion


Deepika Jaiswal[SUP] #[/SUP][SUP] 1 [/SUP], Ujjwal Kumar[SUP] #[/SUP][SUP] 1 [/SUP], Vineet Gaur[SUP] 2 [/SUP], Dinakar M Salunke[SUP] 1 [/SUP]



Affiliations

Abstract

The newly emerged SARS-CoV-2 causing coronavirus disease (COVID-19) resulted in >500 million infections. A great deal about the molecular processes of virus infection in the host is getting uncovered. Two sequential proteolytic cleavages of viral spike protein by host proteases are prerequisites for the entry of the virus into the host cell. The first cleavage occurs at S1/S2 site by the furin protease, and the second cleavage at a fusion activation site, the S2' site, by the TMPRSS2 protease. S2' cleavage site is present in the S2 domain of spike protein followed by a fusion peptide. Given the S2' site to be conserved among all the SARS-CoV-2 variants, we chose an S2' epitope encompassing the S2' cleavage site and generated single-chain antibodies (scFvs) through an exhaustive phage display library screening. Crystal structure of a scFv in complex with S2' epitope was determined. Incidentally, S2' epitope in the scFv bound structure adopts an alpha-helical conformation equivalent to the conformation of the epitope in the spike protein. Furthermore, these scFvs can bind to the spike protein expressed either in vitro or on the mammalian cell surface. We illustrate a molecular model based on structural and biochemical insights into the antibody-S2' epitope interaction emphasizing scFvs mediated blocking of virus entry into the host cell by restricting the access of TMPRSS2 protease and consequently inhibiting the S2' cleavage competitively. This article is protected by copyright. All rights reserved.

Keywords: Antibody scFv; SARS-CoV-2; TMPRSS2 cleavage site; antigen-antibody interaction; phage display scFv libraries; spike protein S2' epitope.
 
Back
Top Bottom